EUCAST technical note on anidulafungin

Clin Microbiol Infect. 2011 Nov;17(11):E18-20. doi: 10.1111/j.1469-0691.2011.03647.x. Epub 2011 Sep 16.

Abstract

The European Committee on Antimicrobial Susceptibility Testing-Subcommittee on Antifungal Susceptibility Testing has determined breakpoints for anidulafungin for Candida spp. This Technical Note is based on the EUCAST anidulafungin rationale document (available at: http://www.eucast.org). Species-specific breakpoints for C. albicans are S ≤0.03 mg/L and R >0.03 mg/L and for C. glabrata, C. tropicalis and C. krusei S ≤0.06 mg/L and R >0.06 mg/L. C. parapsilosis was not regarded a good target for anidulafungin. There are insufficient data to set breakpoints for other species. The breakpoints are based upon pharmacokinetic data, epidemiological cut-off values and clinical experience. Breakpoints will be reviewed regularly.

MeSH terms

  • Anidulafungin
  • Antifungal Agents / pharmacokinetics
  • Antifungal Agents / pharmacology*
  • Candida / drug effects*
  • Echinocandins / pharmacokinetics
  • Echinocandins / pharmacology*
  • Humans
  • Microbial Sensitivity Tests / methods

Substances

  • Antifungal Agents
  • Echinocandins
  • Anidulafungin